Clinical Trial News
Regional Chemotherapy Shows Promise in Treating Colorectal Cancer Metastatic to the Liver
A study involving 93 patients with colorectal cancer metastatic to the liver treated with hepatic arterial infusion of 5-fluorodeoxyuridine (FUDR) showed significant tumor size reduction and prolonged survival, especially in patients without extrahepatic metastases.
D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial
• A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
• The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
• Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.